Marc J. Kaufman, PhD
Director, Translational Imaging Laboratory
- Associate Professor of Psychiatry
Dr. Kaufman is director of McLean Hospital’s Translational Imaging Laboratory, associate professor of psychiatry at Harvard Medical School, co-director of the NIDA T32 post-doctoral training program at McLean, and a Partners Human Research Committee member. He conducts translational research in addiction, psychiatric, and neurodegenerative disorders and received the Jack H. Mendelson Memorial Research Award for outstanding substance abuse research contributions (2010), a NARSAD Independent Investigator Award (2010), and a Rapid Response Innovation Award from the Michael J. Fox Foundation for Parkinson’s Research (2011).
Dr. Kaufman has been a consultant reviewer for the Veteran’s Administration, the Office of National Drug Control Policy, the Wellcome Research Trust, and numerous journals, and is a charter member of the NIH Addiction Risks and Mechanisms study section (2015-2018). He is on the board of directors of the College on Problems of Drug Dependence (2013-2017), and the board of consulting editors of Experimental and Clinical Psychopharmacology.
The creative use of neuroimaging and other techniques is helping McLean scientists better diagnose and develop new treatments for a range of conditions including substance use disorders, neuropsychiatric conditions such as schizophrenia, major depression, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), and neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Dr. Kaufman’s Translational Imaging Laboratory, founded in 2004, executes preclinical, clinical, and translational studies using innovative neuroimaging techniques to investigate the structure, function, and metabolism of the brain. Dr. Kaufman and his lab interpret brain images in the context of additional behavioral and histological (tissue structure) assessments.
Magnetic resonance imaging techniques, including structural imaging (MRI), functional imaging (fMRI), and spectroscopy (MRS), which measures brain chemistry, are noninvasive and thus can be used both in humans and in animals to study multiple aspects of brain structure and function.
Dr. Kaufman’s research goal is to use magnetic resonance imaging methods in preclinical models of addiction, compulsive behavior disorders, HIV, and psychotic disorders, as well as in humans with those disorders, to advance the understanding of pathogenesis and pathophysiology of these disorders and to develop new diagnostic methods and treatments.
Recent projects include a study of mice that develop compulsive grooming behavior thought to model aspects of human obsessive compulsive and related disorders. Using a form of chemical imaging, magnetic resonance spectroscopy, Dr. Kaufman’s group found abnormal brain metabolism and oxidative stress, which parallels findings in humans with compulsive behavior disorders. This work holds promise for enabling earlier diagnosis and treatment of compulsive behavior disorders.
The lab used MRS in a preclinical study of SAPAP3 knockout mice—which model aspects of human obsessive compulsive and related disorders (OCRD)—to determine whether these mice exhibit neurochemical abnormalities found in humans with OCRD. Dr. Kaufman and his staff found low levels of the energy intermediate lactic acid and of the key antioxidant molecule glutathione in knockout mouse striatum. They interpreted this finding as reflecting high levels of striatal metabolism and oxidative stress, consistent with findings in humans with OCRD. Dr. Kaufman’s group collaborated with Dr. Brian Brennan on a human MRS study reporting a brain glutathione reduction in humans with OCD, suggesting that brain oxidative stress is present in animal and human models of compulsive behavior disorders. This could support use of antioxidant treatments to reduce behavioral symptoms of these disorders.
Dr. Kaufman also used MRS to document brain oxidative stress in a mouse model of HIV, Tat protein-expressing GT-tg bigenic mice. The results prompted subsequent testing of an antioxidant, MSM, which reduced depression-like behavior in these mice. This research supports the possibility that antioxidants could be useful for reducing the high prevalence of depression in people living with HIV.
- Jack Bergman, PhD, McLean Hospital
- Brian P. Brennan, MD, MMSc, McLean Hospital
- Fei Du, PhD, McLean Hospital
- Guoping Feng, PhD, Massachusetts Institute of Technology
- James I. Hudson, MD, ScD, SM, McLean Hospital
- Amy C. Janes, PhD, National Institute on Drug Abuse
- Brian D. Kangas, PhD, McLean Hospital
- Stephen J. Kohut, PhD, McLean Hospital
- R. Kathryn McHugh, PhD, McLean Hospital
- Jay McLaughlin, PhD, University of Florida
- Mary Morrison, MD, Temple University
- Dost Öngür, MD, PhD, McLean Hospital
- Carol Paronis, PhD, McLean Hospital
- Harrison G. Pope, MD, MPH, McLean Hospital
- Servio Ramirez, PhD, Temple University
- Scott Rawls, PhD, Temple University
- Robert Ross, PhD, University of New Hampshire
- Gordana Vitaliano, MD, PhD, McLean Hospital
- Roger D. Weiss, MD, McLean Hospital
Kaufman MJ, Janes AC, Frederick BD, Brimson-Théberge M, Tong Y, McWilliams SB, Bear A, Gillis TE, Schrode KM, Renshaw PF, Negus SS. A method for conducting functional MRI studies in alert nonhuman primates: initial results with opioid agonists in male cynomolgus monkeys. Experimental and Clinical Psychopharmacology 2013;21(4):323-31.
Mintzopoulos D, Gillis TE, Robertson H, Dalia T, Feng G, Rauch SL, Kaufman MJ. Striatal magnetic resonance spectroscopy abnormalities in young adult SAPAP3 knockout mice. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2016;1(1):39-48.
Brennan BP, Jensen JE, Perriello C, Pope HG Jr, Jenike MA, Hudson JI, Rauch SL, Kaufman MJ. Lower posterior cingulate cortex glutathione levels in obsessive-compulsive disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2016;1(2):116-124.
Brain Imaging in Substance Abuse: Research, Clinical, and Forensic Applications
by Marc J. Kaufman
Education & Training
- 1983 BA in Biology and Psychology, Wesleyan University
- 1990 PhD in Neurotoxicology and Neuropharmacology, Johns Hopkins University
- 1989-1992 NIH Post-Doctoral Fellow, New England Primate Research Center